Latest Regulatory News

Silver Mines Limited is progressing its Bowdens Silver Project development application with updated ecological surveys, while exploration intensifies at the Rockwell Prospect and Californian assets, supported by a solid cash position.

Prodigy Gold has boosted the indicated resource at its Hyperion Gold Deposit by 70%, lifting total resources to 454,000 ounces and progressing key mining approvals and joint ventures.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Zeotech pushed forward its AusPozz™ metakaolin commercialisation with extended and new MOUs, progressed key Toondoon project approvals amid rising contractor costs, and launched live methane control trials.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.

Bannerman Energy has locked in a landmark US$321.5 million strategic investment from CNNC Overseas Limited, enabling debt-free construction of its Etango Uranium Project and setting the stage for a Final Investment Decision in H2 2026.

Volt Resources has secured a major extension and volume increase to its Bunyu graphite offtake agreement while progressing high purity graphite production and downstream refinery development in the US.

Southern Palladium reported a doubling in chromite recoveries at its Bengwenyama project, prompting a redesign of the processing plant and pushing the DFS completion to late Q4 2026 amid drilling delays and enhanced metallurgical work.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.

Resonance Health reports strong cash flow and progress in clinical trials, with a record forward order pipeline for its Software-as-a-Medical-Device business and profitable trial site clinics.

HyTerra Ltd is progressing its flagship Nemaha hydrogen project with a key production test planned for Q2 2026, while expanding its global footprint through strategic partnerships and a $7 million capital raise.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.